BioSpace News Archive

One month after the beginning of the school year, 80 per cent of school-aged children have returned to school in Beni and Mabalako health zones, the two epicentres of the current Ebola outbreak in the eastern Democratic Republic of the Congo (DRC). More than half of these children are girls.

Mylan N.V. (NASDAQ: MYL) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the District of Delaware’s decision that Teva’s Copaxone® 40 mg/mL dosing patents are invalid as obvious

45,000-square-foot tent on the site of the Baycrest campus will be the venue for some 1,400 guests celebrating the organization’s century of care and innovation, and a future of leading-edge firsts on October 14.

Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced that it will provide an update on its intranasal betahistine program, including key results from the second Phase 1 trial, on Wednesday, October 17, 2018.

Umbilical cord blood is now playing a critical role in the treatment of diseases like leukemia, lymphoma, sickle cell anemia, among others, and the medical industry has been moving toward the commercialization of these promising new therapies.

In today’s global supply chain marketplace, 100% quality production can not only reduce rework costs and improve the bottom line, but it can also increase top-line sales by helping you gain market share.

The public is invited to an open house at the Hollidaysburg Veterans’ Home (HVH) located at 138 Veterans Blvd., Duncansville, on Tuesday, Oct. 16, from 10 a.m. to 1 p.m.

According to data compiled by Arcview Market Research, in partnership with BDS Analytics, the United States’ legal cannabis market is projected to reach USD 11 Billion in consumer spending in 2018 and more than USD 23 Billion by 2023 while growing at a CAGR of 22% during the forecast period.

Mercaptor Discoveries (Mercaptor) today announced that its proprietary Capton® molecule demonstrated efficacy in the Epilepsy Therapy Screening Program (ETSP) run by the National Institutes of Health –National Institute Of Neurological Disorders And Stroke

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that Anthony S. Crisci, Esq., CPA has joined the Company as the General Manager, Chief Compliance Officer & Corporate Counsel for all of NuGenerex’s distribution efforts, including its newly acquired eight (8) pharmacies and laboratory from Veneto Holdings, L.L.C., to lead the Company in building an end-to-end solution for pharmacy and health management services.